Express Scripts at Its Lows With Drug Prices at Center Stage

Lowering drug prices is big in the news, and that’s hampering stocks like Express Scripts (ESRX). But with ESRX at its lows, is this the time to sell?

Read more

Express Scripts is a Solid Value at Eleven Times Earnings

Express Scripts (ESRX) is one drug distributor which didn’t lower earnings estimates last qtr. At 11x earnings the stock is a value, but does come with risk.

Read more

Express Scripts Has Its Issues, But Is a Compelling Value

Express Scripts (ESRX) has its issues, such as uncertainty with its largest customer and political pressure for lower drug prices. But at 11 times earnings, ESRX is a value.

Read more

Express Scripts is a Deal, But It’s Deal With Anthem is Causing Concern

Express Scripts (ESRX) is looking good on the profit front. But investors are overly skittish about the possibility of it losing its biggest customer.

Read more

Anthem Wants Better Drug Prices from Express Scripts

Express Scripts (ESRX) fell after its largest client, Anthem, said it wanted $3 billion in better drug prices. Let’s talk about it.

Read more

Express Scripts Ups Estimates

Express Scripts (ESRX) gets my highest mark for certainty and consistency, and management just upped 2016 profit estimates.

Read more

Conservative Growth

Investors looking for conservative double-digit returns should take a look at Express Scripts (ESRX), but growth investors might want faster growth.

Read more

Lucky Number 13

Express Scripts (ESRX) is expected to grow 13% — both in the next year and beyond.

Read more

11% Growth All Year

Express Scripts (ESRX) is expected to have 11% profit growth every quarter this year.

Read more

Old Dependable

Express Scripts (ESRX) is Old Dependable in my client’s portfolios. Here’s my outlook on ESRX for 2015.

Read more

Page 1 of 41234